Co-morbidity in rheumatoid arthritis

Research output: Contribution to journalReview articlepeer-review

102 Scopus citations


Rheumatoid arthritis (RA) affects approximately 0.5-1% of the population and imposes substantial societal costs including an increased risk of work-related disability and accelerated mortality. It is increasingly clear that RA-related co-morbidities, including cardiovascular disease (CVD), infection, osteoporosis, lymphoproliferative malignancy, and peptic ulcer disease, serve as major determinants of disease-associated outcome. In this review, the impact of these select comorbidities on RA outcome is discussed. In addition, this review explores potential mechanisms underlying their association with RA, the possible iatrogenic role of agents used to treat the disease, and measures aimed at both prevention and treatment of disease-specific co-morbidity.

Original languageEnglish (US)
Pages (from-to)729-752
Number of pages24
JournalBest Practice and Research: Clinical Rheumatology
Issue number5
StatePublished - 2003


  • Cardiovascular disease
  • Co-morbidity
  • Infection
  • Lymphoma
  • Osteoporosis
  • Peptic ulcer disease
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Co-morbidity in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this